CINA CHEST vs qXR-CTR
AI Verdict
Choose CINA CHEST if…
Choose CINA CHEST if your emergency department or radiology practice requires immediate AI-powered triage and notification for life-threatening acute conditions like Pulmonary Embolism and Aortic Dissection. This tool is ideal for rapidly flagging suspected positive findings on CT angiography scans to prioritize critical cases and streamline workflow in high-stakes environments.
View CINA CHEST →Choose qXR-CTR if…
Choose qXR-CTR if your facility needs an automated, AI-driven solution for measuring the cardiothoracic ratio from standard chest X-ray images. This tool is best suited for aiding in the routine assessment of heart size and identifying potential heart failure risk, providing consistent and efficient support for cardiac screening and monitoring.
View qXR-CTR →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CINA CHEST | qXR-CTR |
|---|---|---|
| Pricing | Subscription-based | Unknown |
| Deployment | Cloud-based, On-premise (dedicated hardware), Virtualized (VM, Docker) | Can be deployed on cloud or on-premise. The Qure.ai app receives DICOM studies via DICOM network protocol from medical systems (PACS/Modality) or can import DICOM from the local system. The received DICOM study is processed in Qure's cloud server, and AI-processed reports are displayed on the app. |
| FDA Status | K210237 AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
qXR-CTRWhile CINA CHEST offers a 'one-click solution' and operates as a standalone web application with notifications, qXR-CTR, as part of the broader qXR platform, explicitly features multilingual UI and reporting, along with mobile and desktop access via a dedicated Qure.ai App. This broader accessibility and language support suggest a more comprehensive and flexible user experience.
Clinical Value
CINA CHESTCINA CHEST is FDA-cleared (K210237) for the rapid detection and prioritization of life-threatening Pulmonary Embolism and Aortic Dissection on CT angiography scans, directly impacting emergency triage and patient outcomes. Clinical studies demonstrate its strong performance and ability to reduce interpretation time for critical cases. While qXR-CTR is also FDA-cleared (K231149) and valuable for automated cardiothoracic ratio measurement and heart failure risk assessment on X-rays, its application is generally less time-critical than the acute conditions addressed by CINA CHEST.
Pricing & Value
TieBoth CINA CHEST and qXR-CTR operate on a subscription-based model with pricing details available only upon request or not publicly disclosed. Without specific pricing information or detailed public return-on-investment studies for either product, it is impossible to conduct a meaningful head-to-head comparison on this dimension.
Enterprise Readiness
qXR-CTRBoth tools offer flexible deployment options (cloud, on-premise, hybrid) and claim HIPAA compliance. However, qXR-CTR explicitly details additional certifications such as GDPR, ISO 13485, and IEC 62304, along with multi-region data residency options. These additional certifications and deployment flexibilities indicate a more robust and globally-oriented enterprise readiness posture for Tool B.
Innovation
qXR-CTRCINA CHEST's innovation lies in its AI-powered triage for rapid detection and prioritization of acute, life-threatening conditions like PE and AD on CT scans, transforming emergency workflows. However, qXR-CTR, as part of Qure.ai's broader qXR platform, demonstrates a wider scope of innovation by offering comprehensive multi-finding detection (up to 29 findings) and priority flagging on chest X-rays, significantly enhancing the utility of a common imaging modality for various conditions beyond just CTR measurement.
Support & Docs
qXR-CTRWhile both companies highlight their clinical publications, Qure.ai explicitly mentions a 'Qure.ai App User's Manual' and 'Qure.ai Documentation' for its products. This suggests a more transparent and readily accessible approach to user support and technical documentation compared to Avicenna.AI, for which specific support and documentation details were not found.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CINA CHEST | qXR-CTR |
|---|---|---|
| Tool Name | CINA CHEST | qXR-CTR |
| Company | Avicenna.AI | Qure.ai Technologies |
| Description | AI-powered radiological triage and notification software designed for the rapid detection and prioritization of Pulmonary Embolism (PE) and Aortic Dissection (AD) on CT angiography scans. | AI-powered software that automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk. |
| Primary Function | Radiological computer-aided triage and notification for Pulmonary Embolism (PE) and Aortic Dissection (AD). | Automated measurement of cardiothoracic ratio (CTR) from chest X-ray images. |
| Imaging Modality | CT angiography (Chest and Thoraco-abdominal CT angiography) | Chest X-ray images (posterior-anterior view) |
| Key Detections/Measurements | Pulmonary Embolism (PE) and Aortic Dissection (AD) | Cardiothoracic Ratio (CTR) |
Videos
Demos, reviews, and walkthroughs featuring CINA CHEST and qXR-CTR.